CRTX - CRTX STOCK NEWS

Cortexyme, Inc. (Nasdaq: CRTX) has initiated a Phase 1 clinical trial for its new drug candidate, COR588, a second-generation gingipain inhibitor aimed at treating periodontal disease and other related indications. The trial, which marks an important milestone for the company, is set to enroll up to 64 healthy participants to evaluate safety, tolerability, and pharmacokinetics. Cortexyme's ongoing GAIN Trial targets Alzheimer’s disease, with top-line data expected by mid-November 2021.

Cortexyme, Inc. (NASDAQ: CRTX) announced its participation in H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET. CEO Casey Lynch and COO Chris Lowe will discuss advancements in their pivotal GAIN trial for Alzheimer’s, with top-line data expected by mid-November 2021. The company is focused on developing therapeutics for degenerative diseases, including Alzheimer's and Parkinson's, targeting the infectious pathogen P. gingivalis. A webcast of the event will be available on Cortexyme's investor website, archived for 90 days.

The GAIN Trial analysis by Cortexyme, Inc. reveals significant findings regarding P. gingivalis infection in Alzheimer’s disease. At the Annual Biomarkers for Alzheimer’s Disease Summit, Cortexyme will present results showing that all 472 patients analyzed had anti-P. gingivalis antibodies in cerebrospinal fluid. The trial, pivotal in nature, aims to evaluate the efficacy of atuzaginstat in patients with mild to moderate Alzheimer’s. Top-line data is expected by mid-November 2021. The findings highlight the potential role of P. gingivalis in Alzheimer’s pathologies.

Cortexyme, Inc. (Nasdaq: CRTX) is advancing a pivotal trial for Alzheimer's disease, with top-line data expected by mid-November 2021. The company will present at the Annual Biomarkers for Alzheimer’s Disease Summit on August 25, 2021, sharing new findings on P. gingivalis infection and its connection to Alzheimer's pathology. Speaker Leslie Holsinger, Ph.D. will cover the pivotal Phase 2/3 GAIN Trial, demonstrating the role of neuroinflammation and novel biomarkers in patients with mild to moderate Alzheimer's disease.

Cortexyme, Inc. (Nasdaq: CRTX) announced an update on its pivotal GAIN trial in Alzheimer's disease, with top-line data expected by mid-November 2021. The company emphasizes the causal link between the infectious pathogen P. gingivalis and neurodegeneration. The trial has enrolled 643 patients and is designed to demonstrate a meaningful treatment effect. Additionally, Cortexyme reported financial results for Q2 2021, with a net loss of $21.8 million and a cash position of $153.5 million, expected to fund operations through 2023.

Cortexyme, Inc. (Nasdaq: CRTX) is advancing its pivotal GAIN Trial aimed at treating mild to moderate Alzheimer's disease, with topline data expected in Q4 2021. Chris Lowe, COO and CFO, will participate in a virtual fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:00 p.m. ET. The event's webcast will be available on Cortexyme's Investor Calendar page and archived for 90 days. Cortexyme is focused on developing therapeutics for degenerative diseases, targeting the infectious pathogen P. gingivalis linked to Alzheimer’s pathology.

Cortexyme, Inc. (Nasdaq: CRTX) announced new preclinical data at the Alzheimer's Association International Conference® (AAIC) 2021, indicating a link between P. gingivalis and elevated phospho-tau217, a biomarker for Alzheimer's disease. The findings support the ongoing GAIN Trial, aiming to demonstrate that atuzaginstat (COR388) can significantly slow disease progression. Key data reveals that 100% of GAIN trial patients show P. gingivalis exposure, with new biomarkers indicating a suitable study population. The trial is expected to yield top-line results in Q4 2021.

Cortexyme, Inc. (Nasdaq: CRTX) announced the selection of its lead 3CLpro inhibitor, COR803, aimed at treating coronavirus infections, including COVID-19. This decision follows the growing clinical need for effective coronavirus therapies. With an EC90 of 30 nM, COR803 demonstrates high potency and selective binding, suggesting potential for outpatient and inpatient use. The company is also progressing in its pivotal GAIN Trial for Alzheimer’s disease, with top-line data expected in the fourth quarter of 2021, showcasing its commitment to addressing significant unmet medical needs.

Cortexyme, Inc. (Nasdaq: CRTX) announced updates on its pivotal Phase 2/3 GAIN Trial at the Alzheimer’s Association International Conference 2021 taking place July 26-30 in Denver. Top-line data from the trial is expected in Q4 2021. Cortexyme will present findings related to P. gingivalis, a bacterium implicated in Alzheimer’s pathology, through two posters. Additionally, a corporate symposium titled 'Getting to the Root Cause of Alzheimer’s Disease' will occur on July 27. The company aims to pioneer treatments focused on the infectious aspects of Alzheimer’s.